03:25 PM EDT, 04/24/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) rallied Wednesday after the US Food and Drug Administration approved its generic version of the nasal spray used to treat opioid overdose.

Amneal's Naloxone HCI nasal spray is the generic version of OTC Narcan HCI nasal spray. Emergent BioSolutions ( EBS ) owns the trademark.

AMRX shares were more than 11% higher on Wednesday.

Price: 6.01, Change: +0.61, Percent Change: +11.20